Patents Assigned to Ma'at
  • Use of raman spectroscopy to monitor culture medium
    Patent number: 11249026
    Abstract: In one aspect, the disclosure provides a method of defining a Raman signature of a culture component, the method comprising: obtaining a Raman spectrum of a culture component in a non-interfering or minimally-interfering solution, identifying peaks in the Raman spectrum that are associated with the culture component, obtaining a Raman spectrum of a culture medium comprising the culture component, and, removing peaks of the culture component in the Raman spectrum of the culture medium that are distorted compared to the peaks identified in the Raman spectrum of the culture component in a non-interfering or minimally-interfering solution.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 15, 2022
    Assignee: Biogen MA Inc.
    Inventors: Justin Moretto, Brandon Berry, Alex Doane
  • Methods of treating multiple sclerosis
    Patent number: 11246850
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: February 15, 2022
    Assignee: Biogen MA Inc.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • ANTI-VLA-4 ANTIBODIES
    Publication number: 20210401981
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Application
    Filed: July 2, 2021
    Publication date: December 30, 2021
    Applicant: BIOGEN MA INC.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • SP35 Antibodies And Uses Thereof
    Publication number: 20210395360
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: March 30, 2021
    Publication date: December 23, 2021
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber Stark, Steven D. Miklasz, Christilyn Graff
  • Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof
    Patent number: 11203601
    Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: December 21, 2021
    Assignees: The Broad Institute, Inc., Biogen MA Inc.
    Inventors: Florence Fevrier Wagner, Michel Weiwer, Arthur J. Campbell, Joshua R. Sacher, Edward Holson, Brian Stuart Lucas, TeYu Chen
  • CRYSTALLINE POLYMORPHS OF BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20210387972
    Abstract: Provided are crystalline forms of (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, pharmaceutical compositions, methods of use and methods of making thereof.
    Type: Application
    Filed: October 15, 2019
    Publication date: December 16, 2021
    Applicant: Biogen MA Inc.
    Inventors: Fengmei ZHENG, Anton PETERSON, Kalyan VASUDEVAN, Chaomin LI, Daniel B. PATIENCE, Yiqing LIN
  • COMPOSITIONS AND METHODS FOR DETECTION OF SMN PROTEIN IN A SUBJECT AND TREATMENT OF A SUBJECT
    Publication number: 20210389335
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. Also provided are kits for detecting the amount of SMN protein in a sample of cerebrospinal fluid.
    Type: Application
    Filed: July 1, 2021
    Publication date: December 16, 2021
    Applicant: Biogen MA Inc.
    Inventors: Frank Rigo, Katherine M. Bishop
  • Pharmaceutical bead formulations comprising dimethyl fumarate
    Patent number: 11197842
    Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: December 14, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi
  • Smart injector
    Patent number: 11179523
    Abstract: A device that regulates, monitors, and provides data on the progress of a large-volume injector during its injection sequence. The device comprises an injector and a monitor assembly. The injector has a syringe having a plunger, and a biasing device that biases the plunger through the syringe. The monitor assembly comprises a resistance unit configured to resist movement of the plunger, a gear connected to the plunger by the resistance unit, and a control unit configured to monitor the position, and regulate the rotation, of the gear. Wherein linear movement of the plunger causes the gear to rotate so that the control unit generates information on the position of the plunger.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: November 23, 2021
    Assignee: BIOGEN MA, INC.
    Inventor: Haiming Wu
  • Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
    Patent number: 11174243
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: November 16, 2021
    Assignees: Sunesis Pharmaceuticals, Inc., Biogen MA Inc.
    Inventors: J. Michael Macphee, Linda L. Neuman
  • ASK1 inhibiting agents
    Patent number: 11168095
    Abstract: Provided are compounds of Formulas (I?), (I), (II?) and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: November 9, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Felix Gonzalez Lopez de Turiso, Martin Himmelbauer, Michael J. Luzzio
  • MANGANESE SUPPLEMENTATION FOR CONTROL OF GLYCOSYLATION IN MAMMALIAN CELL CULTURE PROCESS
    Publication number: 20210340584
    Abstract: The present invention pertains to a cell culture medium comprising manganese as a media supplement, which was shown to control recombinant protein glycosylation and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.
    Type: Application
    Filed: November 23, 2020
    Publication date: November 4, 2021
    Applicant: Biogen MA Inc.
    Inventors: Lia Tescione, Thomas Ryll, Alan Gilbert
  • CROSS-SCALE MODELING OF BIOREACTOR CULTURES USING RAMAN SPECTROSCOPY
    Publication number: 20210324321
    Abstract: Aspect of the disclosure relate to methods of assessing a bioreactor culture that involve determining a culture parameter of the manufacturing-scale bioreactor culture using a model that relates a Raman spectrum to the culture parameter. Related bioreactor system are also provided.
    Type: Application
    Filed: January 13, 2020
    Publication date: October 21, 2021
    Applicant: Biogen MA Inc.
    Inventors: Brandon Berry, Justin Moretto
  • Wearable medical detector
    Patent number: 11147524
    Abstract: Various embodiments of medical detector systems as well as their methods of operation are disclosed. In one embodiment, one or more detectors are coupled to wearable structures for detecting at least a first tracer within a body portion. In another embodiment, one or more detectors are coupled to a wearable structure, where the detector corresponds to a CMOS chip that directly detects a first radioactive tracer.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: October 19, 2021
    Assignee: Biogen MA Inc.
    Inventors: Ajay Verma, Marisa J. Bober, Victoria Cabot, Courtney D. Hilliard, Ara N. Knaian, Seth O. Newburg, John William Hoppin, Karl F. Schmidt
  • Synthesis of thiolated oligonucleotides without a capping step
    Patent number: 11142545
    Abstract: The invention herein describes a solid-phase synthetic method for preparing thiolated oligonucleotides without needing a capping step. The methods of the invention comprises repetition of a three-reaction per cycle, namely detritylation, coupling and sulfurization, without a capping step. In some embodiments, the synthetic methods of the present invention can be used for preparing an anti-sense oligonucleotide.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: October 12, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Xianglin Shi, Jimin Yang, William F. Kiesman, Yannick Fillon
  • Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
    Patent number: 11142794
    Abstract: The present invention relates to molecular signatures that can be used to identify patients diagnosed with an autoimmune disease, in particular with systemic lupus erythematosus for treatment with a CD40 or CD40L antagonist such as anti-CD40 antibody, anti-CD40L antibody or a binding fragment thereof. The signatures can also be used to monitor target engagement and response to treatment.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: October 12, 2021
    Assignees: UCB BIOPHARMA SRL, BIOGEN MA INC.
    Inventors: Geoffrey Johnston, Carrie G. Wager, Huo Li, Ann Ranger
  • COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY
    Publication number: 20210308281
    Abstract: Aspects of the application relate to compositions and methods for treating spinal muscular atrophy in a subject. In particular, this application provides therapeutic combinations of a recombinant nucleic acid that encodes the survival of motor neuron 1 (SMN1) protein (e.g., in a viral vector), and an antisense oligonucleotide (ASO) that increases full-length survival of motor neuron 2 (SMN2) mRNA (e.g., that is targeted to a nucleic acid molecule encoding the survival of motor neuron 2 (SMN2) and that promotes the inclusion of exon 7 in SMN2 mRNA).
    Type: Application
    Filed: August 15, 2019
    Publication date: October 7, 2021
    Applicant: Biogen MA Inc.
    Inventors: Anindya Kumar Sen, Alexander McCampbell
  • ARGININE-FREE TNFR:FC-FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF USE
    Publication number: 20210309719
    Abstract: Aspects of the invention are directed to arginine-free polypeptide-containing compositions and methods for treating disorders associated with inflammation or the autoimmune response. In particular, the polypeptide is etanercept.
    Type: Application
    Filed: March 30, 2021
    Publication date: October 7, 2021
    Applicant: Biogen MA Inc.
    Inventors: Kevin Maloney, Ke Gong, Roy Alston
  • ANTI-HSPA5 ANTIBODIES AND USES THEREOF
    Publication number: 20210301002
    Abstract: This disclosure provides anti-HSPA5 antibodies. Also featured is a method for delivering an agent into the brain, spinal cord, or other component of the central nervous system. In addition, methods of identifying a human subject at risk of relapse of neuromyelitis optica (NMO) or neuropsychiatric systemic lupus erythematosus (NP-SLE) are disclosed, as are methods of determining the severity of an attack of NMO or NP-SLE, and methods of diagnosing NP-SLE.
    Type: Application
    Filed: February 23, 2021
    Publication date: September 30, 2021
    Applicants: Biogen MA Inc., The Regents of the University of Colorado, a body corporate
    Inventors: Jeffrey L. Bennett, Richard M. Ransohoff, Fumitaka Shimizu, Kristin L. Schaller
  • Methods of treating multiple sclerosis
    Patent number: 11129806
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: September 28, 2021
    Assignee: Biogen MA Inc.
    Inventors: Mark Novas, Rui (Ray) Zhang